

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

OV56

RRID:CVCL_2673

Type: Cell Line

Proper Citation

RRID:CVCL_2673

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2673

Proper Citation: RRID:CVCL_2673

Description: Cell line OV56 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous adenocarcinoma

Defining Citation: [PMID:7707437](#), [PMID:22460905](#), [PMID:23839242](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28273451](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OV56

Synonyms: OV-56

Cross References: EFO:EFO_0006458, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472428, BioSample:SAMN10987613, cancercellines:CVCL_2673, Cell_Model_Passport:SIDM00475, Cosmic-CLP:1480362, DepMap:ACH-000091, ECACC:96020759, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1480362, GEO:GSM711700, GEO:GSM887481, GEO:GSM888562, GEO:GSM1291146, GEO:GSM1670312, GEO:GSM2474987, IARC_TP53:30138, LiGeA:CCLE_602,

PharmacDB:OV56_1211_2019, PRIDE:PXD030304, Progenetix:CVCL_2673, Wikidata:Q54936898

ID: CVCL_2673

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260920T005351+0000

Ratings and Alerts

No rating or validation information has been found for OV56.

No alerts have been found for OV56.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Meeson KE, et al. (2026) Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer. *Cancer & metabolism*, 14(1).

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Littler S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Wang F, et al. (2022) Stratifying ferroptosis sensitivity in cells and mouse tissues by photochemical activation of lipid peroxidation and fluorescent imaging. *STAR protocols*, 3(2), 101189.

Wang F, et al. (2022) PALP: A rapid imaging technique for stratifying ferroptosis sensitivity in normal and tumor tissues in situ. *Cell chemical biology*, 29(1), 157.

He S, et al. (2017) The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF- κ B signaling pathway. *Journal of experimental & clinical cancer research* : CR, 36(1), 137.